Microbiota, particularly the intestinal bacteriome, plays a central role in host physiology and the composition and activity of this ecosystem is directly influenced by known cancer risk factors such as lifestyle, diet and inflammation. Although intestinal bacteriome has been implicated in the development of various cancer type including colorectal cancer, hepatocarcinoma and pancreatic cancer, accumulating evidence point to a role of microorganism in therapeutics. In this lecture, I will address the relationship between bacteriome and the neutralizing TNFa antibody in controlling colitis-associated colorectal cancer.  In addition, I will show that specific bacterial network is associated with therapeutic efficacy of immune check point inhibitor PD1 against non-small cell lung cancer (NSCLC).  These studies represent the first step toward understanding mechanisms by which microbiota influences therapeutic outcomes and shed light on how alteration of bacteriome could have significant benefit in cancer treatment.

Microbiome as modified of cancer therapeutics

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.